Regression of prostatic hypertrophy by osaterone acetate in dogs

The prostatic regression effect of oral administration of a new steroidal anti−androgen, osaterone acetate, was investigated in dogs with prostatic hypertrophy.To dogs with prostatic hypertrophy, 0.1−1.0 mg/kg of osaterone acetate was orally administered for one week, and the regression rate was observed.It was shown that administration of osaterone acetate at 0.2 mg/kg or higher, sharply regressed prostatic hypertrophy during the early stage.Therefore, this agent may be clinically applicable as a therapeutic agent for benign prostatic hypertrophy.